Search

everythinglearnresearchcommunity

for

Search:↓

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

The conversation is about hair loss treatment progress using 2.5mg oral Minoxidil daily, derma rolling weekly, and Ketoconazole shampoo thrice weekly, with plans to add oral Dutasteride. Users discuss the potential benefits and timing of using Dutasteride for hair recovery.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation discusses using Stemoxydine, a hair growth stimulant considered weaker than Minoxidil, and questions whether applying it twice daily could improve results similar to twice-daily Minoxidil applications.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

KX-826, Breezula, PP405, and Stemson are potential future treatments for hair loss, with varying timelines and mechanisms like blocking DHT and stem cell activation. Users express skepticism about the timeline and mention current options like hair transplants and minoxidil.

The conversation is about two new videos on exosomes, focusing on how they work and a Q&A session about their use. Specific treatments for hair loss are not discussed.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.

A user shared a DIY recipe for a NutraKos-style amino acid mix as a cost-effective alternative to the expensive product, suggesting it as a complementary supplement for hair loss. Another user argued that proven treatments like finasteride and minoxidil are more reliable, questioning the efficacy of the amino acid mix.

A 27-year-old has seen hair regrowth over 5 months using 2ml of 5% minoxidil daily, 50mg of RU58841 daily, and occasional microneedling. Commenters think the results are good and ask about microneedling frequency, needle size, and if ketoconazole shampoo is used.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

A user shared their one-month progress using Minoxidil and RU58841 for hair loss, noting significant shedding after micro-needling and seeking opinions on their regrowth. They stopped micro-needling and added RU58841 to their treatment.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.

A user shared their 5-month hair loss treatment progress using 1mg finasteride, topical minoxidil, biotin, Nizoral shampoo, and weekly dermarolling. Replies noted the user's hair was already thick, and there was interest in trying topical minoxidil.

The conversation is about BosleyMD Revive+ Serum, which uses Y100 Compound instead of Minoxidil. The user is seeking reviews or opinions on this newer product.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. Concerns were raised about delays in product presentations and business strategies.

A user received KX-826 instead of RU58841 and is confused about their order. They are asking if others have experienced similar issues.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.